Activities and Publications
-
The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma
The 2022 WHO classification introduced key changes that affect diagnostic criteria for HLRCC, reinforcing the need for pathologists and clinicians to recognize FH deficiency early to ensure accurate diagnosis and appropriate treatment.